Physician

Chitra Rajagopal, MD

According to 2025 Medicare claims, Chitra Rajagopal, MD (NPI: 1467544312) practices hematology/oncology in the Frederick-Gaithersburg-Bethesda, MD market, with the plurality of this provider's patient population coming from Montgomery, MD. This provider's primary affiliated billing organization is RCCA MD LLC (NPI: 1467800367; TIN: 812588874) and primary practice location at 20850-6319.

Rajagopal's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 782 traditional Medicare patients, billed 219,760 HCPCS/CPT codes, and received $2,484,317 in Medicare payments. The top billing code was 99215 (Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more). Part D data shows 1,640 prescription claims across 360 beneficiaries totaling $5,381,283 in drug costs, led by Brukinsa (Zanubrutinib). DME data shows 24 claims. Open Payments data shows 61 records totaling $4,400. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing did not follow a clear longitudinal pattern. Concurrently, Part D prescription costs have moved from a lower plateau to a higher plateau, from $1,569,111 to $5,381,283. In contrast, DME billing represents a smaller volume and moved sharply higher in recent years, from $3,225 to $20,496.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	936	328,125	$2,814,353
2016	877	254,516	$2,734,228
2017	946	224,257	$2,659,896
2018	941	222,047	$2,913,768
2019	965	344,564	$3,710,655
2020	884	333,626	$3,876,099
2021	934	285,761	$3,547,652
2022	942	229,443	$3,475,378
2023	891	212,073	$2,374,994
2024	782	219,760	$2,484,317

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	246	1,304	$1,569,111
2016	268	1,416	$2,085,112
2017	264	1,228	$2,016,773
2018	281	1,348	$1,841,254
2019	277	1,297	$2,180,927
2020	290	1,416	$3,227,971
2021	278	1,472	$3,813,009
2022	331	1,663	$3,904,650
2023	314	1,521	$3,521,865
2024	360	1,640	$5,381,283

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	11	106	$50,694
2016	22	113	$38,734
2017	11	158	$33,802
2018	26	186	$23,385
2019	12	90	$7,804
2020	13	91	$5,399
2021	40	155	$8,039
2022	11	163	$5,342
2023	13	134	$26,992
2024	12	24	$1,596

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	171	189	$170
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	341	590	$119
96372	Injection of drug or substance under skin or into muscle	162	1,044	$13
36415	Insertion of needle into vein for collection of blood sample	607	2,322	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	741	3,004	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Brukinsa	Zanubrutinib	44	1,320	$675,274
Lenalidomide	Lenalidomide	44	1,232	$648,537
Imbruvica	Ibrutinib	35	980	$588,623
Revlimid	Lenalidomide	24	672	$520,900
Jakafi	Ruxolitinib Phosphate	34	1,260	$514,602

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
L8000	Breast prosthesis, mastectomy bra, without integrated breast prosthesis form, any size, any type	N	12	13	$1,360
J8521	Capecitabine, oral, 500 mg	N	N/R	11	$236

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	59	$4,400	AstraZeneca Pharmaceuticals LP
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	2	$9,000	Cornerstone Specialty Network LLC

Explore More Providers

FAQ

What Medicare data is available for Chitra Rajagopal, MD?

Tedicare shows public-source Medicare data for Chitra Rajagopal, MD (NPI 1467544312), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Chitra Rajagopal, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Chitra Rajagopal, MD?

Chitra Rajagopal, MD is linked to RCCA MD LLC (billing NPI 1467800367) in the available physician profile data.

Does Chitra Rajagopal, MD have Open Payments data?

Chitra Rajagopal, MD has 61 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.